Melanoma vaccine - Ichor Medical Systems/Memorial Sloan-Kettering Cancer Center

Drug Profile

Melanoma vaccine - Ichor Medical Systems/Memorial Sloan-Kettering Cancer Center

Alternative Names: Mouse tyrosinase plasmid DNA vaccine; pINGmuTyr; Xenogeneic tyrosinase DNA vaccine

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ichor Medical Systems; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (IM, Injection)
  • 05 Mar 2008 Ichor initiates enrolment in the final and highest dose level of its phase I trial for melanoma in the US
  • 15 May 2007 Phase-I clinical trials in Malignant melanoma in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top